Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
11 January 2018
E-000141-18
Question for written answer
to the Commission
Rule 130
Liadh Ní Riada (GUE/NGL)

 Subject:  Affordable access to medicines
 Answer(s) 

The European Medicines Agency (EMA) has been operating on behalf of Member States and countries in the European Economic Area since 1995. Its purpose is to ensure that all medicines available on the EU market are safe, effective and of high quality.

Large pharmaceutical companies are currently holding Member State governments to ransom with respect to the prices they are charging for orphan drugs. This has the effect of pitting EU citizens, whose lives are on the line in certain cases, and their families against their governments and by default the EU.

Does the Commission consider that the EMA’s role should be expanded to include responsibility for ensuring EU-wide access to affordable lifesaving medicines?

Should the EMA should have responsibility for negotiating a fair and affordable price for drugs on an EU-wide basis?

Should Member States underpinned by the single market principle be given access to these drugs under a block deal to ensure availability of affordable medicines for patients across the EU?

Last updated: 24 January 2018Legal notice